Global Biodefense Market: Industrial Analysis and Forecast (2020-2026)
Global Biodefense Market was valued $12.3 Bn in 2019 and is expected to reach $xx Bn by 2026, at a CAGR of xx% during the forecast period.
Global Biodefense Market Introduction
Biodefense is defined as the use of medical treatments, such as medicines and vaccines, to protect humans from bioterrorism. In addition, there has been progress in terms of research and public health preparedness to counter biological attacks. Synthetic biology is gaining popularity, mostly for the purpose of utilizing biological organisms to lower disease burdens and improve agricultural outputs.
Global Biodefense Market Dynamics
Factors such as the availability of favorable government initiatives, increased government expenditure in developed nations, and rapid technical developments drive the biodefense market. Every year, governments invest a significant amount of money in vaccine research and development in order to be ready for potential bioterrorism strikes. Because governments choose to be prepared for any form of bioterrorism, pharmaceutical companies in the biodefense industry have a lot more potential.
Several institutes in emerging markets, such as India's Defense Research and Development Organization (DRDO), are researching defensive measures to prevent biological assault. The military is putting forth a lot of effort to prepare for a biological strike. One of the major factors driving the need for biodefense is the steady increase in attention toward raising knowledge about bioterrorism across all nations, as well as many suggestions and meetings to combat such activity, which is one of the primary causes driving the demand for biodefense.
In the last several decades, advances in genetic engineering and biotechnology have made it easier to manipulate these deadly and naturally existing viruses, which may now be re-engineered to cause much more harm.
Furthermore, these organisms are readily available, making biodefense a critical element for governments all over the world. Anthrax, botulism, chemical and nuclear agents, as well as other biological agents, have all been employed as carriers for bioterrorism in the past, causing severe economic damage. As a result of these occurrences, the government has enacted biodefense legislation, treaties, and policies to combat biological threats, minimize risks, and prepare for respond to and recover from bio-incidents. By conducting continuous research to diagnose, treat, and prevent infectious diseases, whether deliberate or naturally occurring, the National Institute of Infectious Diseases has played a critical role in developing medical products and strategies to combat bioterrorism and emerging and re-emerging infectious diseases. The aforementioned factors, as well as the growing risk of infectious disease prevalence, are likely to propel the biodefense market forward.
Global Biodefense Market Segment Analysis
In 2019, the anthrax segment dominated the biodefense market, accounting for 29.6% of total revenue. Over the projection period, the category is predicted to grow at a substantial CAGR of XX%. The biodefense market is divided into anthrax, smallpox, botulism, radiation/nuclear, and others, depending on the product. The anthrax bacteria is categorized as a category 1 biological agent by the National Center for Biotechnology Information because it is easily transmitted from one person to another and has the potential to have a significant public health impact. One of the areas where Project BioShield has invested heavily in vaccine research is anti-anthrax countermeasures. Many firms are testing anthrax vaccines in clinical studies.
In the biodefense market, the other product category is anticipated to grow at the fastest rate throughout the forecast period. Viruses such as viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika and Ebola are included in the other segment. Tularemia, which is extremely contagious and may be deadly, has evolved into a bioweapon. As a result of the recent increase in Zika and Ebola virus infections in several countries, many companies are competing to produce vaccinations. Bavarian Nordic's MVA-BN Filo vaccine protects against the two most frequent forms of viral hemorrhagic fever: Ebola and Marburg virus. The vaccine is currently undergoing phase 3 clinical trials, and the firm has partnered with the National Institute of Allergy and Infectious Diseases in the United States to do so.
To know about the Research Methodology :- Request Free Sample Report
Global Biodefense Market Regional Insights
Over the forecast period, the North American region is expected to dominate the market.
The National Research and Technology Council (NSTC), which is part of the Office of Science and Technology Policy in the United States organizes science and technology, and biosecurity is one of its subjects. To raise awareness, a dedicated website was created with the public, academic researchers, scientific societies, and the biotechnology and pharmaceutical sectors in mind. The increase in government funding in the United States is attributed to various initiatives, such as the BioShield Act, the Biomedical Advanced Research and Development Authority (BARDA), and the Joint Program Executive Office for Chemical and Biological Defense, in order to generate and stockpile sufficient vaccines to be used against anthrax.
For example, the US Department of Health and Human Services stated in 2018 that as part of an emergency preparation strategy, it will spend more than USD 25 million on an anthrax antitoxin. The Coalition for Epidemic Preparedness Innovations (CEPI) announced in May 2018 that USD 25 million has been awarded to improve the research and production of Nipah virus vaccines (NiV). Major market participants including Profectus BioSciences Inc. and Emergent BioSolutions Inc. received this financing.
Due to rising R&D spending, the market for biodefense in APAC is anticipated to grow at the fastest rate of xx% over the forecast period. In addition, the region's biodefense market is being driven by the growing importance of biodefense and the rising threat of hazardous biological elements causing emergencies. Australia and Japan are two of the region's most developed biodefense markets, with well-established vaccine production facilities in both nations.
For more information of visit:https://www.maximizemarketresearch.com/market-report/global-biodefense-market/109282/
Global Biodefense Market Report Scope: Inquire before buying
Global Biodefense Market, by Region
• North America
• Europe
• South America
• MEA
• Asia Pacific
Global Biodefense Market Key Players
• XOMA corporation
• Altimmune Inc.
• Emergent Biosolutions Inc.
• Dynavax Technologies Corporation.
• SIGA Technologies.
• Elusys Therapeutics Inc.
• Ichor Medical Systems.
• Dynport Vaccine Company.
• ClevelandBiolabs.
• Bavarian Nordic.
• Ology Bioservices.
• Alnylam Pharmaceuticals Inc
• ANP Technologies Inc
• General Dynamics Corp.
• GlaxoSmithKline Plc
• Alexeter Technologies LLC
Maximize Market Research offers customization of reports according to the specific requirement of our clients.
This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
